Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | PRLHR | P49683 | 2/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4984728 | 0.87 | GRM5 (0.47) | GRM5P2RX7SLC6A7PRLHRPDE2A | |
| SCHEMBL4992289 | 0.84 | GRM5 (0.49) | GRM5P2RX7 | |
| SCHEMBL4989748 | 0.84 | SMN1; SMN2 (0.55) | GRM5P2RX7 | |
| SCHEMBL4983101 | 0.84 | HPGD (0.49) | GRM5P2RX7 | |
| SCHEMBL4985380 | 0.83 | ALDH1A1 (0.51) | GRM5 | |
| SCHEMBL4985624 | 0.83 | P2RX7 (0.49) | GRM5P2RX7 | |
| SCHEMBL4984930 | 0.81 | P2RX7 (0.56) | GRM5P2RX7 | |
| SCHEMBL4985525 | 0.81 | HSD11B1 (0.47) | GRM5P2RX7SLC6A7PDE2A | |
| SCHEMBL4988578 | 0.79 | TSHR (0.47) | GRM5P2RX7 | |
| SCHEMBL14272293 | 0.78 | TSHR (0.50) | GRM5ELANENAMPTJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | GRM5 231/4885ELANE 1304/4885P2RX7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.